Fig. 3From: Preclinical assessment of intravitreal ramucirumab: in vitro and in vivo safety profileFull-field ERG assessment. a ERG responses prior to drug treatment. b ERG responses after drug treatment. No alteration was seen in ERG before and after treatment (OD injected with ramucirumab; OS injected with BSS). c Electrode placement setup. d RETI-port gamma plus® (Roland Consult, Germany)Back to article page